3/16
08:04 am
nsrx
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold [Yahoo! Finance]
High
Report
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold [Yahoo! Finance]
3/16
07:30 am
nsrx
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
High
Report
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
3/13
09:02 am
nsrx
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing [Yahoo! Finance]
Low
Report
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing [Yahoo! Finance]
3/10
10:44 am
nsrx
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th [Yahoo! Finance]
Medium
Report
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th [Yahoo! Finance]
3/9
08:30 am
nsrx
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
High
Report
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
3/9
08:00 am
nsrx
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
High
Report
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
2/20
08:00 am
nsrx
Nasus Pharma to Participate in Upcoming Investor Conferences
Low
Report
Nasus Pharma to Participate in Upcoming Investor Conferences
2/17
08:00 am
nsrx
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Low
Report
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
2/13
08:00 am
nsrx
Nasus Pharma Announces Closing of $15.0 Million Private Placement
Medium
Report
Nasus Pharma Announces Closing of $15.0 Million Private Placement
2/10
11:03 pm
nsrx
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Low
Report
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
1/20
08:00 am
nsrx
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
High
Report
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder